EUVIMEDEUVIMED entdecken
Crossref

EVs Biodistribution and Antifibrotic Impact in Aged Lung Fibrosis Model

Ilias Amtil-Ouahdi, Fabián Vergara, Carlos Rio, Coral González-Martínez, Andreas Jahn, María Antonia Forteza-Genestra, Antonio Gayá, Javier Calvo, Ernest Sala-Llinas, Bernardino Alcázar Navarrete, Ana Dolores Romero-Ortiz, Marta Monjo und 2 weitere

BioFactors · 2025-05 · 51 (3)

DOI: 10.1002/biof.70021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioFactors, online erschienen am 13.05.2025. Verfasst von Ilias Amtil-Ouahdi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Extracellular Vesicles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary fibrosis (PF) is a progressive, life‐threatening disease marked by excessive scarring of lung tissue. Recently, extracellular vesicles (EVs) have emerged as a promising antifibrotic therapy due to their regenerative and anti‐inflammatory properties. However, the success of EV‐based therapies depends on the route of administration, which can significantly influence their biodistribution and therapeutic effects. Furthermore, in PF, aging is a significant risk factor for the disease and, until today, EV treatment efficacy has not been studied in aged tissues. Specifically, we studied EVs derived from human umbilical cord mesenchymal stem cells and compared the biodistribution of these vesicles delivered via three routes: intravenous (IV), intrapleural (IP), and intratracheal (IT). A protocol was developed to set EV staining and concentration, minimizing animal use while maximizing the accuracy of results. To evaluate therapeutic effects, we conducted three experimental setups: (i) to assess their ability to reverse established fibrosis; (ii) to evaluate their effect on fibrosis progression; and (iii) to study early inflammation and macrophage polarization. Lung fibrosis and inflammation were assessed by analyzing fibrotic markers, inflammatory cytokines, collagen deposition, and bronchoalveolar lavage (BAL) fluid cell analysis, providing insights into EVs therapeutic potential in aged, fibrotic lung tissue. In the biodistribution study, IV administration was identified as the most effective route, successfully delivering EVs to both normal and fibrotic lung tissues. In the therapeutic study, antifibrotic effects were observed only when EVs were administered prophylactically, before the establishment of fibrosis. Under this protocol, IV‐administered EVs reduced fibrotic mRNA biomarkers, collagen deposition, inflammatory cell infiltration, and macrophage polarization in BAL, as well as altering cytokine. Our findings emphasize the critical importance of selecting the appropriate route of administration for EV‐based therapies. Notably, our work with an aging model reveals that EV treatments primarily exhibit prophylactic effects, with a marked reduction in their regenerative potential compared to previous studies conducted in younger models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary FibrosisExtracellular VesiclesAnimalsHumansMesenchymal Stem CellsDisease Models, AnimalMiceLungTissue DistributionMacrophagesMaleCytokinesAgingBleomycinBronchoalveolar Lavage Fluid

Stichwörter der Autor:innen

aging modelanti‐inflammatory propertiesextracellular vesiclespulmonary fibrosisregenerative therapiesroute of administration

Substanzen

CytokinesBleomycin

Autor:innen und Institutionen

  • Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain.
  • Cell Therapy and Tissue Engineering Group, Research Institute on Health Sciences (IUNICS), Palma, Spain.
  • GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, Granada, Spain.
  • Fundació Banc de Sang i Teixits de les Illes Balears (FBSTIB), Palma, Spain.
  • Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
  • Respiratory Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain.

ORCID-Profile: Joana M Ramis, Francisco G Ortega

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Amtil-Ouahdi, I., Vergara, F., Rio, C., González-Martínez, C., Jahn, A., Forteza-Genestra, M. A., Gayá, A., Calvo, J., Sala-Llinas, E., Navarrete, B. A., Romero-Ortiz, A. D., Monjo, M., Ramis, J. M., & Ortega, F. G. (2025). EVs Biodistribution and Antifibrotic Impact in Aged Lung Fibrosis Model. BioFactors, 51(3). https://doi.org/10.1002/biof.70021

Vancouver

Amtil-Ouahdi I, Vergara F, Rio C, González-Martínez C, Jahn A, Forteza-Genestra MA, et al. EVs Biodistribution and Antifibrotic Impact in Aged Lung Fibrosis Model. BioFactors. 2025;51(3). doi:10.1002/biof.70021

BibTeX
@article{AmtilOuahdi2025,
  author = {Amtil-Ouahdi, Ilias and Vergara, Fabián and Rio, Carlos and González-Martínez, Coral and Jahn, Andreas and Forteza-Genestra, María Antonia and Gayá, Antonio and Calvo, Javier and Sala-Llinas, Ernest and Navarrete, Bernardino Alcázar and Romero-Ortiz, Ana Dolores and Monjo, Marta and Ramis, Joana M and Ortega, Francisco G},
  title = {EVs Biodistribution and Antifibrotic Impact in Aged Lung Fibrosis Model},
  journal = {BioFactors},
  year = {2025},
  volume = {51},
  number = {3},
  doi = {10.1002/biof.70021}
}
Kostenlos starten →